Frankfurt
30.12.25 | 10:38
0,068 Euro
+6,92 % +0,004
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | Klaria Pharma Holding AB: Klaria accelerates its business development work in collaboration with BDO | 613 | GlobeNewswire (Europe) | With Klaria's product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP's UK Life Sciences & Healthcare M&A team... ► Artikel lesen | |
| 17.12.25 | Klaria Pharma Holding AB: Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application | 81 | GlobeNewswire (Europe) | Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.... ► Artikel lesen | |
| 26.11.25 | Klaria Pharma Holding AB Q3 Sales Decline | - | RTTNews | ||
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2025 | 115 | GlobeNewswire (Europe) | Klaria Interim Report
1 July - 30 September 2025
Summary of the interim reportThird quarter of 2025
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.08.25 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2025 | 236 | GlobeNewswire (Europe) | Klaria interim report
1 April-30 June 2025
Summary of the interim reportSecond quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses... ► Artikel lesen | |
| 18.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.06.2025 | 617 | Xetra Newsboard | Das Instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 18.06.2025 The instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY is traded ex capital... ► Artikel lesen | |
| 28.02.25 | Klaria Pharma Holding AB: Klaria Year-End Report 2024 | 263 | GlobeNewswire (Europe) | Klaria year-end report 1 Jan - 31 Dec 2024
Summary of the reportFourth quarter of 2024
The group in total
- Net sales 1.1 MSEK (1.3 MSEK)
- Other income 0.0 MSEK (0.3 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 10.01.25 | Klaria Pharma Holding AB: Klaria signs license agreement for Sumatriptan Alginate film in Europe with CNX Therapeutics | 429 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has signed a license agreement for Sumatriptan Alginate Film (the "Product"), a pharmaceutical product based on... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 46,150 | +0,16 % | Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026? | ||
| DERMAPHARM | 39,350 | +0,38 % | DERMAPHARM HOLDING SE kracht ab - jetzt wird's brutal spannend! | ||
| SYNBIOTIC | 2,750 | -1,61 % | Original-Research: SYNBIOTIC SE (von NuWays AG): BUY | Original-Research: SYNBIOTIC SE - from NuWays AG
19.12.2025 / 09:26 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| INCYTE | 83,70 | -0,62 % | Incyte Japan gibt die Zulassung von Minjuvi (Tafasitamab) in Kombination mit Rituximab und Lenalidomid zur Behandlung von rezidiviertem oder refraktärem follikulärem Lymphom bekannt | Incyte Biosciences Japan G.K. gab heute bekannt, dass das japanische Ministerium für Gesundheit, Arbeit und Soziales (MHLW) Minjuvi (Tafasitamab) in Kombination mit Rituximab und Lenalidomid für erwachsene... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,695 | -0,07 % | Tilray, Green Thumb & Co: Trump lockert Cannabis-Regeln | US-Präsident Donald Trump hat mit einer neuen Executive Order einen tiefgreifenden Kurswechsel in der amerikanischen Cannabispolitik angestoßen. Künftig soll Marihuana nicht mehr in die strengste Kategorie... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,390 | +6,11 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces the Sale of Holy Crap Foods as It Focuses on Accelerating Its QSR Businesses | Toronto, Ontario--(Newsfile Corp. - December 22, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food... ► Artikel lesen | |
| CSPC PHARMA | 0,914 | -1,68 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | ||
| TONIX PHARMACEUTICALS | 14,000 | +0,72 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) | Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia... ► Artikel lesen | |
| KHIRON LIFE SCIENCES | 0,029 | -100,00 % | Khiron Life Sciences Corp: Khiron Life Sciences warrants to expire Nov. 26 | ||
| PSYCHED WELLNESS | 0,008 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Launches Calmer, a 2x Version of Calm and an Enhanced Flavour Profile for Calm | Toronto, Ontario--(Newsfile Corp. - November 27, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company specializing in the production... ► Artikel lesen | |
| OPKO HEALTH | 1,118 | +1,58 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| COSMO PHARMACEUTICALS | 114,00 | -0,87 % | Cosmo Pharmaceuticals N.V.: Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions | Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 2,750 | -3,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| LEEF BRANDS | 0,128 | -6,57 % | LEEF Brands Inc.: LEEF Brands Announces Full Early Conversion of CAD Convertible Debentures | VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) -- LEEF Brands, Inc. (CSE: LEEF, OTCQB: LEEEF) ("LEEF" or the "Company"), a leading multi-state operator, today announced the full early... ► Artikel lesen |
KLARIA PHARMA HOLDING AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,004 (+6,92 %) liegt der Kurs bei 0,068 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.